Last reviewed · How we verify

EXPAREL 20 mL

Pacira Pharmaceuticals, Inc · FDA-approved active Small molecule ✓ Verified Jun 2026 Quality 2/100

EXPAREL 20 mL is a Small molecule drug developed by Pacira Pharmaceuticals, Inc. It is currently FDA-approved. Also known as: bupivacaine liposome injectable suspension.

EXPAREL 20 mL is a formulation of bupivacaine liposome injection used to treat pain in various conditions, including total knee replacement, knee arthroplasty, trauma, and acute pain. It is a type of local anesthetic that works by blocking nerve signals to provide pain relief.

At a glance

Generic nameEXPAREL 20 mL
Also known asbupivacaine liposome injectable suspension
SponsorPacira Pharmaceuticals, Inc
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about EXPAREL 20 mL

What is EXPAREL 20 mL?

EXPAREL 20 mL is a Small molecule drug developed by Pacira Pharmaceuticals, Inc.

Who makes EXPAREL 20 mL?

EXPAREL 20 mL is developed and marketed by Pacira Pharmaceuticals, Inc (see full Pacira Pharmaceuticals, Inc pipeline at /company/pacira-pharmaceuticals-inc).

Is EXPAREL 20 mL also known as anything else?

EXPAREL 20 mL is also known as bupivacaine liposome injectable suspension.

What development phase is EXPAREL 20 mL in?

EXPAREL 20 mL is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing